Private Client Services LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

Private Client Services LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,861 shares of the biotechnology company’s stock, valued at approximately $629,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atlas Capital Advisors LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $51,000. Northwestern Mutual Wealth Management Co. boosted its stake in United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 65 shares during the period. Neo Ivy Capital Management bought a new position in United Therapeutics in the 2nd quarter worth approximately $48,000. Zions Bancorporation N.A. bought a new position in shares of United Therapeutics during the 1st quarter valued at approximately $66,000. Finally, Quantbot Technologies LP bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $87,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the sale, the director now owns 4 shares in the company, valued at $896. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the transaction, the director now directly owns 4 shares of the company’s stock, valued at $896. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 124,990 shares of company stock worth $29,301,585. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on UTHR shares. HC Wainwright reiterated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush restated an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. Finally, Wells Fargo & Company increased their price target on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $292.67.

United Therapeutics Stock Up 1.1 %

Shares of UTHR stock traded up $2.49 on Monday, hitting $235.08. The stock had a trading volume of 328,012 shares, compared to its average volume of 430,178. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $229.42 and a 200 day moving average price of $228.22. The company has a market cap of $11.06 billion, a PE ratio of 11.72 and a beta of 0.52. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period in the previous year, the company posted $2.67 earnings per share. The firm’s quarterly revenue was up 25.1% on a year-over-year basis. Research analysts anticipate that United Therapeutics Co. will post 23.46 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.